Skip to content
Screener

Bristol-Myers Squibb BMY Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Incyte logo
IncyteINCY
——
Alkermes logo
AlkermesALKS
——

Other financials

Income statement

See full
Revenue$13.0B+5.7%
Gross profit$9.2B+3.9%
Net income$3.3B+153%
EPS (diluted)$1.62+153%

Balance sheet

See full
Cash & equivalents$8.7B-30.8%
Total debt$43.3B-12.3%
Total equity$22.3B+28.0%
Total assets$87.6B-7.4%

Cash flow

See full
Operating cash flow$3.4B-13.4%
CapEx$305.0M-15.5%
Free cash flow$3.1B-13.2%

Valuation

See full
Market cap$132.2B+41.4%
Enterprise value$166.81B+28.0%
P/E14.2×-4.5×
P/S2.7×+0.7×

Profitability

See full
Gross margin70.2%-0.1pp
Net margin18.9%+8.4pp
FCF margin23.3%-7.3pp

Returns & leverage

See full
Return on equity46.7%+17.8pp
Debt / equity1.9×-0.9×
Current ratio1.5×+0.3×

Where this comes from

Reported directly by Bristol-Myers Squibb in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 11:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000014272-26-000020
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Divestiture gains and royalties(176)(585)
Acquired IPRD941,695
Equity investment (gains)/losses, net(248)100
Contingent consideration fair value adjustments—336
Other adjustments22(2)
Changes in operating assets and liabilities:
Receivables504(469)
Inventories(22)(165)

Item 1. FINANCIAL STATEMENTS

FAQ

What is Bristol-Myers Squibb's contingent consideration fair value adjustments?
Bristol-Myers Squibb (BMY) reported contingent consideration fair value adjustments of $0 in Q2 2026.
How has Bristol-Myers Squibb's contingent consideration fair value adjustments changed year-over-year?
Bristol-Myers Squibb's contingent consideration fair value adjustments decreased by 100.0% year-over-year, from $336M to $0.
What is the long-term trend for Bristol-Myers Squibb's contingent consideration fair value adjustments?
Over 4 years (2021 to 2025), Bristol-Myers Squibb's contingent consideration fair value adjustments has grown at a -10.3% compound annual growth rate (CAGR), from -$542M to $351M.
What does contingent consideration fair value adjustments mean?
This reflects the periodic adjustments to the fair value of earn-out provisions or milestone payments related to past business acquisitions. These adjustments are driven by changes in the probability or timing of achieving specific clinical, regulatory, or commercial targets. It serves as a barometer for the success of acquired R&D pipelines.

Ask your AI about Bristol-Myers Squibb's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude